Fadly is a Singapore Registered Patent Attorney specialising in biomedical, pharmaceutical and life sciences-related technologies. He has extensive experience drafting and prosecuting patent applications related to molecular biotechnology such as antibodies and peptides for therapy, fusion/targeting proteins for drug delivery, gene therapy, vaccines, transgenic plants, pharmaceutical compounds, medical diagnostics and the like.

Prior to joining Marks & Clerk, Fadly has worked in law firms and in a leading boutique intellectual property firm in Singapore, where he managed a large portfolio of patent applications covering all of the major IP offices around the world. Fadly also has conducted numerous prior art searches for multinational corporations and has experience in providing validity, infringement, and freedom-to-operate (FTO) analyses to large MNCs and other pharmaceutical companies.

Fadly holds a BSc (Hons) in Life Sciences, from the National University of Singapore and a Master’s degree in IP & Innovation Management (MIPIM) from the Singapore University of Social Sciences (SUSS).

He has been awarded two book prizes by the Association of Singapore Patent Attorneys (ASPA) for being the top scorer of Paper B (Amendment of a Patent Specification) and Paper C (Infringement and Validity of Singapore Patent) in the Singapore Patent Agents Qualifying Examination.

Fadly is currently working towards a qualification as a Chartered (UK) Patent Attorney.